MMED:CC News and Press, MIND MEDICINE INC. From 10/10/23

Governor Gavin Newsom of California has vetoed a measure that would legalize a number of psychedelics and establish a pathway for regulated access. In his message regarding the veto, the governor urged the legislature to present a new resolution in 2024 that created guidelines for regulated ac...

Psychedelics have taken over the mainstream public’s attention in recent years due to increasing reports on their potential mental-health benefits . A growing body of scientific literature has found that psychedelics may be effective at treating a plethora of mental-health conditions at s...

– Preclinical data in ASD model demonstrate the differences between MM-402 (R-MDMA), S-MDMA and Racemic MDMA with enhanced pro-social effects and reduced hyperactivity – Mind Medicine (MindMed) Inc (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “Mi...

Psychedelics are projected to enjoy a compound annual growth rate (CAGR) of 55% and achieve a $7.2 billion valuation by 2029. A recent report from data and analytics firm GlobalData revealed that the psychedelic drug market is poised to experience robust growth before the end of the decade th...

New research has revealed that a single dose of psilocybin, the main psychoactive agent in psychedelic mushrooms, can boost neuroplasticity in users. Scientists found that the psychedelic was capable of inducing neural changes that were associated with reductions in depression symptoms. Neur...

Recent research published in the “ International Journal of Mental Health and Addiction ” has indicated that psychedelic use may result in reduced cocaine intake. The study found that while psychedelic users reported either reducing or completely stopping their intake of cocaine , ...

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that Robert Barrow, Chief Executive Officer of MindMe...

A collective of trained and experienced psilocybin facilitators in Oregon has launched the country’s first psilocybin-assisted recovery program for addicts. The program is the result of a partnership between Nexus Center for Consciousness and a team of licensed psilocybin facilitators ca...

– 198 participants dosed across 20 clinical sites – – On track for topline results in Q4 2023 – Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (NEO: MMED) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company ...

Researchers from the Langone Center of Psychedelic Medicine at New York University and the Imperial College London’s Center for Psychedelic Research have published a study suggesting that small doses of MDMA could help reduce the uncomfortable effects of psilocybin and LSD. Psychedelics ...